CRYOPDP published the results of the first patient dosing in TOPICAL, a trial testing POLB 001 in people with relapsed or refractory multiple myeloma receiving teclistamab.
Public source
Publisher name
Public post
Could cytokine release syndrome be prevented before symptoms begin? The first patient has been dosed in TOPICAL, a trial testing POLB 001 in people with relapsed or refr…
Company
CRYOPDP
Lifescience & Healthcare Supply Chain Solutions
- Industry
- Transportation, Logistics, Supply Chain and Storage
- Location
- Roissy Charles de Gaulle cedex | France, FR
- Company size
- 201–500 employees
About CRYOPDP
Everything began with a commitment to serve the life sciences and healthcare industries by offering global transport and innovative temperature-controlled logistics solutions. Being one of the market leaders in our sector and dedicated to the clinical trial and cell & gene therapy communities, we are operating in more than 150 countries intending to improve the health of people around the world. Truly focused on our customer and patient needs, we, through a dedicated team, plan, manage and implement a tailor-made temperature-controlled solution to fit your requirements and business goals. Count on us to deliver your life-saving goods worldwide - Count on CRYOPDP!
See moreLatest activity
Latest activity from CRYOPDP
9 signals
Research & Knowledge
CRYOPDP tested FLASH proton therapy in 10 people with painful bone metastases in the chest, near the heart, lungs and spinal cord.
Products & Services
CRYOPDP coordinates collection and delivery timings, handling instructions, site access, communication, and monitoring around sensitive shipments with a White-Glove logistics service.
Research & Knowledge
CRYOPDP announced that the first patient has joined the DELUMA randomised phase 2 trial for HER2-negative metastatic breast cancer patients whose disease has progressed after prior treatment.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Poolbeg Pharma plc
Poolbeg Pharma plc published a National Health Executive article highlighting the real-world challenge CRS creates through the need for close monitoring and treatment once it occurs, with Professor Rakesh Popat co-chief investigator of the TOPICAL trial evaluating POLB 001 as a potential oral preventative treatment for CRS in patients with multiple myeloma receiving bispecific antibody therapy.
Research & Knowledge
Bristol Myers Squibb
Bristol Myers Squibb announced positive topline results from a registrational Phase 2 trial evaluating an investigational CAR T cell therapy in certain patients with relapsed or refractory multiple myeloma.
Research & Knowledge
HaemaLogiX Ltd
HaemaLogiX Ltd spotlighted the first patient treated in the KOALA trial, which is evaluating Haemalogix's novel KMCAR T-cell therapy approach for patients with multiple myeloma.
Research & Knowledge
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is working on its lead program, cemsidomide, in clinical trials to explore potential therapy for patients with relapsed/refractory multiple myeloma.
Research & Knowledge
CellsBin® Inc.